Abstract
Dengue, first reported as a travel case in Nepal in 2004, was initially confined to the lower plains, but has spread to higher elevations. It occurred as large outbreaks in 2022 and 2023 (54,784 and 51,243 cases, respectively), reaching every district (n=77). We calculated dengue incidence in each district in 2022 and 2023, via digitizing case data from Nepal’s Ministry of Health and Population, and 2021 census data from the National Statistics Office. Incidence and peak dengue months in each year were mapped, and spatial clusters (hotspots and cold spots) and spatial outliers of incidence rates for the two years were identified using Local Moran’s I. In 2022, district-wise peak cases occurred in August – October. One hotspot (High-High) including six districts around Kathmandu, and one cold spot (Low-Low) comprising eight high elevation districts in Nepal’s northwest region were identified. In 2023, cases peaked March-November, indicating more distributed peaks, starting earlier; hotspots shifted to north-central and eastern regions, and a Low-High outlier district in the central region was identified. Identifying timing of peaks, and spatial clusters of dengue incidence can inform targeted management, improving effectiveness and cost-efficiency. This study provides a baseline examination of recent dengue in Nepal, highlighting timing and spatial clustering in incidence. The mountainous northwest cold spots align with expectations of fewer mosquitoes due to geography and climate. However, dengue peaked in all 77 districts over three months in 2022, suggesting ecological and climatic factors may no longer be effective barriers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SB and SJR were supported by NSF BII 2213854
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: the Epidemiology and Disease Control Division (EDCD) of the Ministry of Health and Population, Nepal https://edcd.gov.np/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.